“Natural” describes an origin, not an interaction profile. St. John’s wort is a useful example because the concern is not just theoretical. Human studies show that an herb taken for mood can change how the body handles certain medicines—including cancer treatment.
The lesson is not that every botanical is dangerous. It is that the exact herb, preparation and medication list matter more than the reassuring words on a bottle.
Evidence at a glance
Population: Five people with cancer receiving irinotecan. Intervention: Oral St. John’s wort during a crossover drug-interaction study. Finding: Exposure to the active metabolite SN-38 fell by 42%. Limit: This measured drug handling, not survival or tumor response. Action: Arrange an oncology-pharmacist review before starting or stopping it.
What the small trial actually measured
In the 2002 randomized crossover study, participants received intravenous irinotecan with and without St. John’s wort. The research regimen used 900 mg of the oral herb daily for 18 days. This is a description of an interaction experiment, not a safe dose suggestion.
SN-38 exposure, measured across time in the blood, was 42% lower with the herb; the 95% confidence interval ranged from 14% to 70% lower. Because each participant was studied under both conditions, the comparison helps isolate an interaction despite the tiny sample.
The study also observed less suppression of blood-cell production. That is not evidence that adding the herb makes chemotherapy safer: less toxicity can accompany less exposure to the active drug. The trial did not show how much, if at all, cancer outcomes changed. Nor does 42% less exposure mean 42% less treatment effectiveness.
Why the warning extends beyond one paper
A systematic review of 22 interaction trials found recurring reductions in conventional-drug exposure. Most studies were small, many used before-and-after designs, and 17 enrolled healthy volunteers rather than patients. Not every tested combination showed an important interaction. This supports a medication-specific warning, not a claim that every medicine behaves identically.
The NCI’s professional interaction review describes effects on drug-metabolizing enzymes and transporters, including CYP3A4 and P-glycoprotein, and human findings involving other anticancer drugs such as imatinib. These systems influence how much medicine reaches or remains in the body.
A supplement’s effect on those systems cannot be assessed by how well someone feels. A reassuring scan or absence of side effects is not a substitute for checking the combination. Product differences also make it unwise to assume that a different bottle removes the concern.
Mood deserves treatment, too
NCCIH notes evidence of benefit for some mild-to-moderate depression, but uncertainty for severe depression and longer-term use. Those findings are not proof of benefit for cancer-related distress specifically. Combining St. John’s wort with certain antidepressants can cause serious serotonin-related effects; photosensitivity and digestive symptoms are other concerns.
If someone is already taking it, the next step is a prompt discussion with the oncology team or pharmacist about a coordinated plan—not independently changing cancer-drug doses or abruptly stopping prescribed antidepressants. The reason for taking it still needs attention. Ask about psycho-oncology support, counseling and medication options compatible with the treatment plan.
Practical questions for the care team
Does my exact cancer treatment interact with this herb? Could any mood, sleep or “wellness” blend contain it? What should I do if I have already taken it? Do any medicines need closer monitoring when the supplement changes? What safer options address the symptom I hoped to treat?
Bring the ingredient label, dose and dates of use. See our Evidence Explorer record.
Evidence checked October 18, 2026. Educational review, not individualized medical advice. Research doses and schedules are not personal prescriptions. Explore the Missing Script article library and the podcast—coming soon.
